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Open access under CC BYVCP/p97/Cdc48 is a hexameric ring-shaped AAA ATPase that participates in a wide variety of cellular
functions. VCP is a very abundant protein in essentially all types of cells and is highly conserved among
eukaryotes. To date, 19 different single amino acid-substitutions in VCP have been reported to cause
IBMPFD (inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia),
an autosomal dominant inherited human disease. Moreover, several similar single amino acid substitu-
tions have been proposed to associate with a rare subclass of familial ALS. The mechanisms by which
these mutations contribute to the pathogenesis are unclear. To elucidate potential functional differences
between wild-type and pathogenic VCPs, we expressed both VCPs in yeast cdc48 mutants. We observed
that all tested pathogenic VCPs suppressed the temperature-sensitive phenotype of cdc48 mutants more
efﬁciently than wild-type VCP. In addition, pathogenic VCPs, but not wild-type VCP, were able to rescue a
lethal cdc48 disruption. In yeast, pathogenic VCPs, but not wild-type VCP, formed apparent cytoplasmic
foci, and these foci were transported to budding sites by the Myo2/actin-mediated transport machinery.
The foci formation of pathogenic VCPs appeared to be associated with their suppression of the temper-
ature-sensitive phenotype of cdc48 mutants. These results support the idea that the pathogenic VCP
mutations create dominant gain-of-functions rather than a simple loss of functional VCP. Their unique
properties in yeast could provide a convenient drug-screening system for the treatment of these diseases.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
VCP, a member of the AAA (ATPase associated with diverse cel-
lular activities) family, is one of the most abundant and ubiquitous
intracellular proteins (Jentsch and Rumpf, 2007; Stolz et al., 2011;
Yamanaka et al., 2011). VCP participates in diverse cellular activi-
ties, including ubiquitin–proteasome-mediated protein degrada-
tion, endoplasmic reticulum (ER)-associated degradation (ERAD),
and ER and Golgi membrane fusions. Recent studies revealed that
VCP also functions in autophagy and endolysosomal sorting (Ju
and Weihl, 2010; Ritz et al., 2011). To perform such diverse func-
tions, VCP appears to differentially utilize its cofactors, which
amounts, so far, to about 30 proteins (Madsen et al., 2009; Yeung
et al., 2008). In addition, many amino acid residues in VCP are
post-translationally modiﬁed throughout the protein via oxidation,associated with Paget disease
ophic lateral sclerosis; GFP,
imura), fax: +81 75 753 7676
imura), kakizuka@lif.kyoto-u.
-NC-ND license.phosphorylation, and acetylation to regulate the function of VCP
(Koike et al., 2010; Mori-Konya et al., 2009; Noguchi et al., 2005).
In addition to its various cellular roles, VCP was identiﬁed as a
binding protein of the Machado-Joseph disease (MJD) protein with
expanded polyglutamines (Hirabayashi et al., 2001). Subsequently,
by genetic screening using Drosophila polyglutamine disease mod-
els, the Drosophila homologue of VCP, ter94, was identiﬁed as a
modiﬁer of expanded polyglutamine-induced eye degeneration
(Higashiyama et al., 2002). In addition, VCP was found to co-local-
ize with abnormal protein aggregates or ubiquitin-positive inclu-
sion bodies in patient-derived neurons representative of several
neurodegenerative disorders such as MJD, Huntington disease, Par-
kinson disease, or motor neuron diseases such as ALS (Hirabayashi
et al., 2001; Ishigaki et al., 2004; Mizuno et al., 2003), suggesting
that VCP is widely involved in different neurodegenerative diseases
(Kakizuka, 2008).
The idea has been further supported by the discovery of mis-
sense mutations in the human VCP gene from patients suffering
from IBMPFD (Inclusion body myopathy associated with Paget’s
disease of bone (PDB) and frontotemporal dementia (FTD)), a rare,
complex, late-onset, and ultimately lethal disorder with autosomal
dominant inheritance (OMIM 167320) (Kimonis et al., 2000; Watts
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been reported from IBMPFD patients (I27V, R93C, R95C/G, P137L,
R155C/H/P/S/L, G157R, R159H/C, R191Q, L198W, A232E, T262A,
N387H, A439S) (Ju and Weihl, 2010). In addition, four missense
mutations (R155H, R191Q, R159G, D592N) in VCP were recently
proposed to cause familial ALS with autosomal dominant inheri-
tance (Johnson et al., 2010).
It has been reported that pathogenic VCPs cause various cellular
defects, including disruption of ERAD (Weihl et al., 2006), impair-
ment of aggresome formation (Ju et al., 2008), defective autophagy
(Ju et al., 2009), and impaired endolysosomal sorting (Ritz et al.,
2011). In cultured cells, pathogenic VCP showed altered binding
abilities for cofactor(s) and ubiquitin (Fernandez-Saiz and Buch-
berger, 2010; Manno et al., 2010). In addition, biochemical studies
revealed that pathogenic VCP adopted nucleotide-dependent al-
tered conformations and had an increased ATPase activity com-
pared to wild-type VCP (Halawani et al., 2009; Manno et al.,
2010; Tang et al., 2010; Fernandez-Saiz and Buchberger, 2010).
Several lines of evidence implicate the involvement of TDP-43 in
the pathogenesis of IBMPFD in neurons (Ritson et al., 2010; Weihl
et al., 2008). However, detailed molecular mechanisms underlying
IBMPFD still remain largely unknown.
The yeast Saccharomyces cerevisiae provides a useful experimen-
tal system for elucidating molecular mechanisms in biological pro-
cesses, due to the ease of genetic manipulations. Since many
functions are conserved between yeast Cdc48 and mammalian
VCP, we expressed human wild-type and pathogenic VCPs in yeast
Cdc48 mutant strains, and characterized their induced phenotypes.2. Materials and methods
2.1. Yeast strains
A list of yeast strains used in this study is provided in Sup. Ta-
ble 1. The cdc48-1 strain (Y255) was created by mating DBY2030
(cdc48-1) with W303 twice (Moir et al., 1982), and the cdc48-3
strain in a W303 background (Y202) was described previously
(Kimura et al., 2009). W303 ADE+(Y1043) was obtained by trans-
forming a PCR-ampliﬁed DNA fragment containing ADE2 with
300 bp of ﬂanking regions from both upstream and downstream
of ADE2. Gene deletions for Dbni1, Ddoa10, Dpre9, Dshe4, Dufd2,
Dsmy1, and Dbni1 were made with the PCR-based method using
pYM1 (Janke et al., 2004; Knop et al., 1999). Gene deletion for
Dbnr1 was achieved using FA6a-natNT2. Carboxyl-terminal tag-
ging with 9xmyc for Myo2 and with 6xHA for Ufd1 or Shp1 were
performed using pYM18 and pYM16, respectively. For the disrup-
tion of CDC48, ﬁrst, an XhoI fragment carrying HIS3 was excised
from a plasmid and inserted into the SalI site of CDC48 (nt 434
to +2585) in BSII. Then the resultant plasmid was linearized and
transformed into W303 diploid cells.2.2. Antibodies
The afﬁnity-puriﬁed rabbit polyclonal anti-VCP and rabbit poly-
clonal anti-Cdc48p antibodies were developed previously (Hira-
bayashi et al., 2001; Noguchi et al., 2005). The following
antibodies used in this study were purchased: mouse monoclonal
anti-actin (Chemicon); mouse monoclonal anti-GFP for Western
blot (Roche) or for immunostaining (Invitrogen); rabbit polyclonal
anti-GFP (Molecular Probes); mouse monoclonal anti-HA (Roche);
mouse monoclonal anti-c-myc for immunoprecipitation (9E10,
Santa-Cruz); rabbit polyclonal anti-c-myc for immunostaining
(CM100, Gramsch Laboratories); mouse monoclonal anti-yeast
PGK antibody (Molecular Probes, Eugene, OR); Alexa Fluor 488 goat
anti-mouse IgG and Alexa Fluor 594 goat anti-rabbit IgG (Molecu-lar Probes); sheep polyclonal anti-mouse IgG-HRP and donkey
anti-rabbit IgG-HRP (GE Healthcare).
2.3. Plasmids
A list of plasmids used in this study is provided in Sup. Table 2.
The VCP expression plasmids (pRS316UPD-VCP or pRS316GPD-
pathogenic VCP), in which VCP or pathogenic VCP are under the
GPD promoter in pRS316, were created as follows. First, a BamHI
and EcoRI fragment with the GPD promoter was inserted into the
BamHI and EcoRI sites of pRS316 to create 316-GPD. Then BamHI
and NotI fragments of VCP or pathogenic VCPs from pBS II KS(+)
VCPs were inserted into the BamHI and NotI sites of 316-GPD
(Mori-Konya et al., 2009). The VCP-EGFP plasmids were created
by ligating BglII–NotI fragments from pEGFP-N-VCP with 316-
GPD. For the plasmids expressing VCPs under the control of the
CDC48 promoter, the CDC48 promoter region from 434 to 1
was ampliﬁed by PCR using genomic DNA as a template with the
following primers: (AATTGTCGACCAGCCCAAGAAACGGACTTCGA
TAAGTTGG, AATTGGATCCGATTTGTATATCTGTCTTGTAGTTGAGC-
CA). The PCR fragment was then cut with SalI and BamHI, and li-
gated with the BamHI–SalI vector region of pRS316GPD-VCP or
pRS316GPD-pathogenic VCPs. The plasmid expressing CPY-GFP
was a kind gift from Y. Saeki. To create TRP1-based vectors,
pRS314 was used instead of pRS316. Initially, protein expression
of VCP[R95G] was undetectable, probably due to the codon usage
of GGC for glycine. We changed the GGC to GGT, and could observe
the protein expression of VCP[R95G] in yeast.
2.4. Growth assay of yeasts
Yeast cell densities were adjusted to OD600 = 1.0, and diluted
serially by 10-fold dilutions. Each diluted sample was spotted on
the plates. Cells were incubated for 3 days at the indicated
temperatures.
2.5. Immunoblotting
For Fig. 1D and Sup. Fig. 4B, whole-cell extracts for Western
blotting were prepared as described previously (Kushnirov,
2000), and for other experiments, as described previously (Kimura
et al., 2001).
To measure the level of CPY⁄-GFP, cells were grown to mid-log
phase at 30 C, and treated with 50 lg/ml of cycloheximide. Cells
were further incubated at 30 C, and harvested at the indicated
times. Western blotting analysis was performed using anti-GFP
and anti-PGK.
2.6. FACS analysis
Cells were treated with 15 lg/ml nocodazole for 120 min,
washed twice with water, and suspended in medium. Then the
temperature was shifted. At the indicated times, cells were ﬁxed
in 70% ethanol, resuspended in a Tris–citrate buffer (180 mM
Tris–HCl (pH 7.5), 180 mM NaCl, 70 mMMgCl2, 50 mM sodium cit-
rate), brieﬂy sonicated, and digested with 0.25 mg/ml RNase in the
same buffer for 1 h at 50 C. DNA was stained with 50 lg/ml propi-
dium iodide, and 50,000 cells from each sample were scanned with
a FACScan ﬂow cytometer (BD Biosciences) as described previously
FL2H = 37(Threshold).
2.7. Microscopic analysis of EGFP-fusion proteins
For the observation of EGFP-fusion proteins in Figs. 4, 5B–E, 6B
and C, 7A–C, cells were imaged at room temperature using an OLY-
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40X/0.90 1/0.11-0.23/FN26.5.
2.8. Rhodamine–phalloidin staining
Cells at early log phase (1–3  106/ml, 10 ml) were ﬁxed by
adding one-tenth volume of 37% formaldehyde and incubating at
25 C for 30 min. Cells were harvested, washed twice with PBS by
centrifugation at 3000 rpm for 2 min, and suspended in 200 ll of
PBS, and sonicated brieﬂy. Half of the cells were treated with 5 U
of rhodamine–phalloidin (Molecular Probes) for 10 min, washed
with PBS three times, and suspended in 50 ll of PBS. Cells were im-
aged at room temperature using a confocal microscope (LSM510;
Carl Zeiss) equipped with Plan-Apochromat 100 oil objective
lenses. Images were acquired as z sections of 0.37 lm. Images were
processed in the LSM image browser, and brightness and contrast
were adjusted using Adobe Photoshop CS4.
2.9. Immunostaining analysis
Yeast cells in early log-phase were ﬁxed with 3.7% formalde-
hyde for 1 h, and washed twice with buffer B (20 mM potassium
phosphate pH 7.4, 1.2 M sorbitol). Cells were treated with Zymol-
yase (ﬁnal 0.5 mg/ml) in buffer B plus 0.17% of 2-mercaptoethanol,
and incubated at 30 C for 10 min. Cells were centrifuged at
5000 rpm for 1 min, then washed three times with buffer B. Swell-
ing buffer (20 mM MES pH 6.0, 150 mM potassium acetate, 5 mM
magnesium acetate, 750 mM sorbitol) was added and cells were
incubated at room temperature for 20 min. Cells were mounted
on a cover slip for 5 min, then treated with methanol for 5 min
and acetone for 5 min. Mount blocking solution (2% skim milk
and 0.1% Tween20 in PBS) was added to the cover glass for
30 min, and anti-GFP and anti-myc antibodies in blocking bufferFig.1. Effective suppression of temperature-sensitivities of cdc48-3 and cdc48-1 by pathog
promoter on the growth of cdc48-3 and cdc48-1. The cdc48 mutant cells with or withou
plates, and grown at the indicated temperatures for 3 days. (B) Effects of the expression o
on SGal uracil () plates, and grown at the indicated temperatures for 3 days. (C) Effec
growth of wild type cells. (D) Expression levels of various VCPs and Cdc48 proteins in cdc
VCP antibody. PGK serves as a control for loading. Note that yeast Cdc48 cross-reactedwere incubated at 4 C overnight. Secondary antibodies (Alexa488
anti-rabbit IgG, Alexa594 anti-mouse IgG) were incubated at room
temperature for 2 h and washed twice with PBS containing BSA (ﬁ-
nal 0.01 mg/ml). Cells were imaged using a confocal microscope
(LSM510; Carl Zeiss) equipped with Plan-Apochromat 100 oil
objective lens. Images were acquired as z sections of 0.37 lm.
2.10. Time-lapse imaging
Cell morphologies and GFP signals were recorded every 10 min
using an inverted ﬂuorescence microscope (Axiovert 200M; Carl
Zeiss). Image analysis and processing were performed via the Zeiss
AxioVision 4.5 software.
2.11. Statistical analysis
Each experiment was conducted at least three times with con-
sistent results. The gel or blot representative of each experiment
is presented in this study. The statistical signiﬁcance was analyzed
using Student’s t test against the corresponding values of the wild
type.
3. Results
3.1. Rescue of temperature-sensitive growth of cdc48 mutants by the
expression of pathogenic VCPs but not wild-type VCP
To elucidate potential disease-related functions of pathogenic
VCPs, we expressed wild-type VCP (wtVCP) and pathogenic VCPs
(R93C, R95G, R155C, R155H, R155P, R159H, R191Q, and A232E) in
yeast S. cerevisiae. Since porcine VCP, which is 70% identical to yeast
Cdc48 at the amino acid level, has been shown not to be able to
complement a cdc48 null mutation (Madeo et al., 1997), we ex-enic VCPs. (A) Effects of the expression of various VCPs under the control of the GPD
t exogenously expressed VCPs or Cdc48 were diluted and spotted on SD uracil ()
f various VCPs under the GAL promoter on the growth of cdc48-3. Cells were spotted
ts of the expression of VCP, VCP[R155C] or CDC48 under the GPD promoter on the
48-3 and cdc48-1. Cells grown at 25 C were analyzed by Western blot using an anti-
with anti-VCP antibody as shown.
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cold-sensitive (cs) cdc48-1mutants under the control of the consti-
tutive GPD promoter. The amino acid sequences of wild-type hu-
man, rat, and mouse VCPs are 100% identical and are 70%
identical to yeast Cdc48. The expression of wtVCP partially sup-
pressed the ts growth of cdc48-3 but not the cs growth of cdc48-1
(Fig. 1A). Surprisingly, we observed that eight pathogenic VCPs
tested here were all able to rescue the temperature-sensitive
growth of both cdc48-3 and cdc48-1mutants (Fig. 1A). Similar phe-
notypeswere also observed by expressing VCPs under the control of
the galactose-inducible GAL promoter (Fig. 1B). In these experi-
ments, all of the GAL promoter-induced mutant VCPs (R155C,
R155H, R155P, R159H, R191Q, and A232E), efﬁciently rescued the
ts phenotype of the cdc48-3 mutant both at 34 C and 37 C,
whereas wtVCP rescued only at 34 C. Expression of pathogenic
VCP[R155C] in wild-type cells did not affect the growth phenotypes
both at 25 and 37 C (Fig. 1C). We conﬁrmed that the expression
levels of all VCPs including wtVCP were mostly equivalent
(Fig. 1D). Thus, the observed difference between wtVCP and the
pathogenic VCPs appeared not to be due to the levels of proteins,
but rather due to their intrinsic activities. Since these pathogenic
VCPs have increased ATPase activities (Halawani et al., 2009; Man-
no et al., 2010), we examined whether VCP[T761E], a mutant with
the highest ATPase activity known (Mori-Konya et al., 2009), had
an even better ability to suppress the ts phenotypes than the path-
ogenic VCPs (Fig. 1A and B). However, VCP[T761E] behaved more
like wtVCP and was not able to suppress the ts phenotypes as effec-
tively as the pathogenic VCPs, suggesting that the increased ATPase
activities of the pathogenic VCPs were not related to the suppres-
sion of the temperature-sensitive cdc48 mutant phenotypes.
In addition, pathogenic VCPs (R155C or A232E) were expressed
under the CDC48 promoter (nt 434 to1, with respect to the start
of transcription), resulting in expression levels that were only aboutFig.2. Complementation of the lethal cdc48 null mutant by pathogenic VCPs. (A) Dip
expression plasmid for Cdc48, wtVCP, VCP[R93C], VCP[R95G], VCP[R155C], VCP[R191Q]
expressed under its cognate promoter, and wild-type and pathogenic VCPs were expresse
in (i)–(iv) (each tetrad is displayed horizontally). (B) Expression levels of VCP and Cdc48
serves as a loading control.to1/10–1/15 relative to proteins expressedunder theGPDpromoter.
Nevertheless, they still rescued the temperature-sensitivity of
cdc48-3, though the suppression was less effective than in cells
expressing themutant protein under theGPD promoter (Sup. Fig. 1).
We then examined whether the expression of pathogenic VCP
(via the GPD promoter) could rescue the cell cycle defects of
cdc48 mutations (Sup. Fig. 2A). To differentiate between wtVCP
and pathogenic VCP in liquid culture more clearly, the tempera-
tures of 32.5 C and 35.5 C were chosen, since not only wtVCP
but also pathogenic VCP did not seem to have any effect on cell cy-
cle progression of cdc48-3 mutants in liquid culture at 37 C. Cells
were ﬁrst synchronized with nocodazole, released and shifted to
32.5 C and 35.5 C, then analyzed by FACS analysis based on
DNA contents. At 32.5 C, we found that the cell cycle arrest ob-
served in cdc48-3 was rectiﬁed by the expression of both wtVCP
and VCP[R155C]. By contrast, at 35.5 C, the arrest was rescued
by the expression of VCP[R155C] but not wtVCP (Sup. Fig. 2A).
3.2. Rescue of the lethal cdc48 null mutation by pathogenic, but not
wild-type, VCP
The result that pathogenic VCPs but not wtVCP allowed cdc48
temperature-sensitive mutants to grow at restrictive temperatures
led us to examine whether pathogenic VCPs were also able to res-
cue a cdc48 null mutation. For this purpose, we introduced a URA3-
based plasmid expressing wtVCP or pathogenic VCPs under the
GPD promoter into a diploid Dcdc48 heterozygote strain (CDC48/
cdc48::HIS3). After these diploids sporulated, they were dissected.
As Cdc48 is essential, usually only two colonies arose from the
Dcdc48 heterozygote. In segregants of the diploids expressing
pathogenic VCP [R93C, R95G, R155C, R191Q, or A232E], but not
wtVCP, we often obtained small colonies in addition to two colo-
nies of a regular size (Fig. 2A). All of the small colonies wereloid strain (Dcdc48::HIS3/CDC48) transformed with or without a URA3-containing
, or VCP[A232E], was dissected after sporulation. In these experiments, Cdc48 was
d under the GPD promoter. In each tetrad analysis, four sets of segregants are shown
proteins were examined for his+, ura+ segregants obtained from each tetrad. PGK
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when the pathogenic VCP-expressing plasmid was transmitted to
the cdc48::HIS3 segregant. Similar results were obtained using a
Dcdc48::kanR/CDC48 strain, another heterozygote (data not
shown). By Western blot analysis of these his+ ura+ cells, we con-
ﬁrmed that pathogenic VCP but not Cdc48 was expressed (Fig. 2B).
In addition, DNA sequence analysis of plasmids recovered from
these cells conﬁrmed the presence of the respective pathogenic
VCP mutations (data not shown). In segregants of the diploids
expressing wtVCP, we observed only two colonies at most from
40 different tetrad analyses.
To exclude the possibility that plasmid transmission through
meiosis was defective in the cells expressing wtVCP, we performed
a plasmid swapping assay using 5-FOA, a compound that kills ura+
cells. A cdc48 null mutant that was rescued by a URA3 plasmid
expressing Cdc48 was transformed with a TRP1 plasmid expressing
wtVCP, pathogenic VCPs or Cdc48. After culturing on uracil-con-
taining plates to let cells drop the URA3 plasmid, cells were
streaked on 5-FOA plates. Only cdc48 null mutants that could sur-
vive without the URA3 plasmid grow on the 5-FOA plates. As ex-
pected, cells expressing pathogenic VCPs or Cdc48 grew but not
wtVCP were able to grow on 5-FOA plates (Sup. Fig. 3).
Since the expression of pathogenic VCPs under the control of
the CDC48 promoter rescued the temperature-sensitivity of
cdc48-3 to a certain extent (Fig. S1), we investigated whether the
same pathogenic VCPs driven by the CDC48 promoter could also
rescue a null mutation of cdc48. We found that the lethality of
the cdc48 null mutation was not rescued (data not shown). Thus,
these results indicate that a sufﬁcient amount of pathogenic VCPs,
but not wtVCP, was able to rescue the cdc48 null mutation.Fig.3. Degradation of CPY⁄-GFP. (A) Wild-type and cdc48-3 cells with or without an exp
VCP[R155C], or VCP[A232E] were grown at 30 C to mid-log phase. They were treated wit
CPY⁄-GFP was examined byWestern blot using an anti-GFP antibody. (B) Quantiﬁcation o
in (A). Data are mean ± SE values of three independent experiments. In each experimen3.3. Partial rescue of Cdc48 activities by expression of wild-type VCP
and pathogenic VCPs
We then examined whether pathogenic VCPs were able to res-
cue another characteristic defect of the Cdc48 mutation, namely
the impaired ability to degrade CPY⁄, a Cdc48-speciﬁc substrate
(Ye et al., 2001). In the cdc48-3 mutant, degradation of CPY⁄-GFP,
a GFP-tagged CPY⁄, was delayed, and expression of Cdc48 rescued
the defect (Fig. 3). We found that the expression of wtVCP partially
rescued the CPY⁄-GFP degradation defect in cdc48-3 cells. Expres-
sion of VCP[R155C] and VCP[A232E] also partially rescued the deg-
radation defect in cdc48-3 cells, to a similar extent as wtVCP, but
were not as robust as for Cdc48. These results suggest that the dif-
fering capacities of the wild-type and pathogenic VCPs to rescue
the growth defects of cdc48 mutants are not attributable to differ-
ences in the ability to degrade Cdc48 substrates.
3.4. Foci formation of pathogenic VCPs
To further differentiate between wtVCP and pathogenic VCPs,
we examined the localization of these VCPs. To observe their local-
ization, we expressed VCPs fused with EGFP. We ﬁrst veriﬁed that
EGFP-fused VCPs functioned similarly to non-tagged VCPs. EGFP-
fused pathogenic VCPs suppressed the temperature sensitivity of
cdc48-3 much more efﬁciently than wtVCP-EGFP (Sup. Fig. 4).
Moreover, EGFP-fused pathogenic VCPs (R155C, R191Q, A232E)
as well as CDC48-EGFP, but not wtVCP-EGFP, rescued a null
mutation of cdc48 (Sup. Fig. 4). In cdc48-3 cells, Cdc48-EGFP and
wtVCP-EGFP showed a diffuse localization throughout the cells
(Fig. 4A). Interestingly, VCP[R155C]-EGFP exhibited a smallression plasmid for CPY⁄-GFP, with or without plasmids expressing Cdc48, wtVCP,
h cycloheximide (50 lg/ml), and harvested at the indicated times. The expression of
f the amount of CPY⁄GFP in (A). Protein levels were quantiﬁed from the bands shown
t, the amount of CPY⁄-GFP at time 0 was deﬁned as 100%.
Fig.4. Foci formation of pathogenic VCPs. (A) Foci formation in cdc48-3 cells expressing VCP[R155C]-EGFP or VCP[A232E]-EGFP, but not in cdc48-3 cells expressing wtVCP- or
Cdc48-EGFP. The cdc48-3 cells with the indicated plasmids were cultured to an early log phase and examined by ﬂuorescence microscopy. (B) Foci formation in wild-type cells
expressing VCP[R155C]-EGFP, but not in cells expressing wtVCP-, VCP[T761E]-, VCP[K524A]-, or Cdc48-EGFP.
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rescence (Fig. 4A). These foci were not localized within the nucleus,
when counterstained by Hoechst (data not shown). We observed
quite similar GFP-foci in VCP[A232E]-EGFP-expressing cells
(Fig. 4A). Moreover, the GFP foci were not uniquely observed in
cdc48-3 cells: we observed similar VCP[R155C]-EGFP foci in wild-
type yeast cells (Fig. 4B). Immuno-staining using an anti-VCP anti-
body yielded a similar result: VCP[R155C] formed foci, but wtVCP
did not (Sup. Fig. 5). Furthermore, neither VCP[K524A]-EGFP nor
VCP[T761E]-EGFP formed foci (Fig. 4B). These results indicate that
focus formation was associated with pathogenic VCP mutations,
but was not directly linked to different ATPase activities of VCPs.
It has been shown that these pathogenic VCPs adopt different
ATP-dependent conformations from wtVCP (Halawani et al.,
2009; Tang et al., 2010). Moreover, in mammalian cells, all tested
pathogenic VCPs formed aggregates much more efﬁciently than
wtVCP, when they were expressed either with the co-expression
of polyglutamines or with the treatment of proteasome inhibitors
(Ju et al., 2008; Manno et al., 2010). In addition, Cdc48 was re-
ported to be included in an aggresome (Wang et al., 2009). Thus,
it is easy to speculate that these foci may be simple aggregates
incorporating the pathogenic VCPs. However, considering that
pathogenic VCPs are better able to suppress the defects of cdc48
mutants, these foci may be functional complexes, or otherwise
beneﬁcial to the cdc48 mutants. Indeed, as both nocodazole and
benomyl treatment did not affect the localization and appearance
of the foci, it is not likely that the foci are aggresomes (Fig. 5B
and C, and data not shown). Rather, we noticed that the GFP foci
were often localized at the buds (Fig. 4).3.5. Involvement of actin cables in foci formation of pathogenic VCPs
We speculated that there might be a speciﬁc mechanism to gen-
erate VCP[R155C]-EGFP foci at buds. It is known that in budding
yeasts many organelles and vesicles are conveyed toward buds
by polarized transport utilizing actin cables as rails (Pruyne et al.,
2004b). We therefore examined whether actin was involved in
the localization of the foci at buds. First, we examined whether
VCP[R155C]-EGFP foci were co-localized on actin by phalloidinstaining. Indeed, VCP[R155C]-EGFP foci in buds were partially co-
localized on the phalloidin-positive structures (Fig. 5A). Next, we
examined whether actin cables were required for the speciﬁc local-
ization of foci at buds by treating cells with Latrunculin B (LatB),
which inhibits actin polymerization by sequestering actin mono-
mers (Ayscough et al., 1997; Irazoqui et al., 2005). After LatB treat-
ment, we observed that the VCP[R155C]-EGFP foci disappeared;
instead, multiple small punctate structures appeared throughout
the cell (Fig. 5B and C). When LatB was washed out from the med-
ium, the VCP[R155C]-EGFP foci were reformed, and the foci moved
to buds (Fig. 5D and E). By time-lapse analysis, we observed that
the VCP[R155C]-EGFP-containing small punctae started to fuse to
make foci and then the foci moved to buds (Sup. Fig. 6). Treatment
with nocodazole, MG132, tunicamycin, or heat shock did not
change the appearance of the foci (Fig. 5B and C), indicating that
the effect of LatB was speciﬁc. These results demonstrated that ac-
tin cables were required for the formation of the foci as well as
their transport to buds.
We investigated the involvement of actin cables in more detail.
Actin cables are ﬁlamentous structures that emanate from a site of
polarized growth in budding yeast (Fig. 6A) (Pruyne et al., 2004b).
In budding yeast, the assembly of actin cables is controlled by the
formins Bni1 and Bnr1. Bni1 nucleates actin cables that originate in
the bud, whereas Bnr1 polymerizes actin cables at the bud neck
(Pruyne et al., 2004a). We therefore examined whether
VCP[R155C]-EGFP foci formed in Dbni1 and Dbnr1 cells. Similar
to the results with LatB-treated cells, GFP ﬂuorescence of
VCP[R155C]-EGFP showed multiple punctae in Dbni1 cells and
Dbnr1 cells (Fig. 6B and C). The alteration of GFP patterns was
much clearer in Dbni1 cells than in Dbnr1 cells. In contrast, GFP
ﬂuorescence remained diffuse in Dbni1 and Dbnr1 cells expressing
wtVCP-EGFP or Cdc48-EGFP (Fig. 6B and C). VCP[R155C]-EGFP foci
formation was tested in other mutant cells, and was not impaired
in a Pre9 (a proteasome subunit) mutant, a Doa10 (ubiquitin ligase
in ERAD) mutant, or a Ufd2 (ubiquitin chain assembly factor) mu-
tant, suggesting that UPS machinery was not involved in the foci
formation (Fig. 6C).
We next examined whether the VCP[R155C]-EGFP foci forma-
tion at buds was related to its function in the suppression of
Fig.5. Involvement of actin cables in the formation and localization of VCP[R155C] foci at buds. (A) Phalloidin staining. Wild-type cells (Y1043) expressing VCP[R155C]-EGFP
in early log phase were ﬁxed, stained with rhodamine–phalloidin, and analyzed by confocal microscopy. (B) Latrunculin B, nocodazole, heat shock, MG132 and tunicamycin
treatment. Wild-type cells expressing VCP[R155C]-EGFP were treated with Latrunculin B (25 lg/ml) for 2 h, nocodazole (15 lg/ml) for 2 h, a heat shock of 37 C for 2 h,
MG132 (200 lM) for 4 h, or with tunicamycin (2 lg/ml) for 4 h at 25 C, and the cells were examined by ﬂuorescence microscopy. (C) Quantiﬁcation of (B). Cells containing
less than 5 bright GFP foci throughout the cell were counted among a total of 100 cells in (B), and mean values of three experiments are shown. SD are shown as bars. Note
that a decrease of cells with foci (n < 5) indicates a reciprocal increase of cells with numerous punctae (5 6 n). (D) Re-formation of VCP[R155C]-EGFP foci after washing out of
Latrunculin B. Wild-type cells expressing VCP[R155C]-EGFP were treated with Latrunculin B (25 lg/ml in DMSO) for 2 h, washed twice with 1% DMSO, incubated in medium
with 1% DMSO, and examined at the indicated times by ﬂuorescence microscopy. (E) Quantiﬁcation of (D). Results are shown, as described in (C). Note that an increase of cells
with foci (n < 5) indicates reciprocal decrease of cells with only punctae (5 6 n).
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double-mutant strains cdc48-3 Dbni1 and cdc48-3 Dbnr1, ex-
pressed VCP[R155C]-EGFP in these mutants, and grew them at
restrictive temperatures. The suppression activity of VCP[R155C]-
EGFP on the growth defects was partially lost in both cdc48-3
Dbnr1 and cdc48-3 Dbni1 cells at the restrictive temperature of
37 C but not at 34 C (Fig. 6D). The Dbni1 single mutant cells grew
well at either 25 C or 37 C, and the growth of Dbni1 cells was not
affected by the expression of wtVCP, VCP[R155C], or CDC48 (Sup.
Fig. 7). These results support the idea that focus formation of
VCP[R155C]-EGFP at buds was required for suppression of the
cdc48 ts mutation.3.6. Involvement of Myo2 in foci formation of pathogenic VCPs
Of the ﬁve myosins in yeast, it is notable that Class V myosins
(Myo2, and Myo4) are motor proteins or cages that transport their
cargos toward the plus ends of actin ﬁlaments. The cargos include
vacuoles, small organelles, secretary vesicles, and components of
TGN (Trans Golgi Network) (Trybus, 2008). While Myo4 mediates
the transport of mRNA and movement of ER tubules, Myo2 plays
a major role in the transport of secretory vesicles, vacuoles, and
segregation of membrane-bound organelles (Matsui, 2003). There-
fore, we next examined the formation and the movement of
VCP[R155C]-EGFP foci in two temperature-sensitive myo2 mutant
Fig.6. Effects of BNI1 and BNR1. (A) schematic drawing of the actin-mediated transport machinery of a budding cell. (B) GFP ﬂuorescence images of wtVCP-, VCP[R155C]-, or
CDC48-EGFP in Dbni1 and Dbnr1 mutants. (C) Quantiﬁcation of foci formations in various mutants, as indicated. Results are shown, as described in Fig. 5C. Note that a
decrease of cells with foci (n < 5) indicates a reciprocal increase of cells with numerous punctae (5 6 n). (D) Growth of cdc48-3, cdc48-3Dbnr1, cdc48-3Dbni1, cdc48-3Dsmy1
expressing EGFP, wtVCP-, VCP[R155C]-, or Cdc48-EGFP at the indicated temperatures.
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defective in its actin binding domain, and in myo2-20 cells its tail
domain is defective in cargo binding (Johnston et al., 1991; Schott
et al., 1999). In both mutants, VCP[R155C]-EGFP ﬂuorescence ap-
peared as multiple small punctate structures, which were similar
to those observed in Dbni1 and Dbnr1 cells, as well as LatB-treated
cells (Fig. 7A and B). Frequencies of foci localization in buds also
signiﬁcantly decreased in both of the myo2 mutants (Fig. 7A and
C). Moreover, in a strain with a deletion of Smy1, a kinesin-related
protein that interacts with Myo2 (Beningo et al., 2000), small mul-
tiple punctae were also observed (Fig. 7A–C). Consistent with the
formation of small punctae, a partial loss of suppression by
VCP[R155C]-EGFP was observed in cdc48-3 Dsmy1 cells at the
restrictive temperature, 37 C (Fig. 6D). By contrast, VCP[R155C]-
EGFP foci formation was retained in a myo1 mutant and a Dshe4
mutant whose function is required for Myo4, Myo3, and Myo5,
thus conﬁrming the speciﬁc involvement of Myo2 (Figs. 6C and
7A–C). Attempts to make double mutants of myo2-66 cdc48-3
and myo2-20 cdc48-3 were unsuccessful (data not shown).In addition, we observed the co-localization, albeit partial, of
Myo2 and VCP[R155C]-EGFP in wild-type cells (Fig. 7D), which fur-
ther supports the idea that Myo2 is responsible for the transport of
VCP[R155C]-EGFP itself or a VCP[R155C]-EGFP-containing cargo(s).
Interestingly, VCP[R155C]-EGFP did not co-localize with actin in
the myo2-66 mutant, though the localization of actin did not ap-
pear to change, as compared to wild-type cells (Fig. 7E). These re-
sults suggest that the interaction between VCP[R155C]-EGFP foci
and actin was not direct; rather, the interaction was mediated by
Myo2.
We next attempted to demonstrate physical interactions be-
tween VCP[R155C]-EGFP and Myo2 by co-immunoprecipitation
analysis (Sup. Fig. 8). Under conditions in which VCP[R155C]-
EGFP interacted with Ufd1-6HA and Shp1-6HA efﬁciently, we
could not clearly detect interactions between VCP[R155C]-EGFP
and Myo2. Thus, although VCP[R155C]-EGFP and Myo2 were
apparently co-localized, their interaction might not be direct;
there might be a protein or proteins that link VCP[R155C] and
Myo2.
Fig.7. Myo2-dependent VCP[R155C] foci formation and its transport to buds. (A) GFP ﬂuorescence images of VCP[R155C]-EGFP. Wild-type, myo2-66, myo2-20, Dsmy1, and
myo1 cells expressing VCP[R155C]-EGFP were grown at 25 C. In myo2-66 and myo2-20 mutants, cells were shifted to 37 C for 2 and 4 h. Upper panels, GFP ﬂuorescence;
middle panels, phase contrast; lower panels, merged. (B) Quantiﬁcation of cells with foci throughout the cell in (A). Results are shown, as described in Fig. 5C. Note that a
decrease of cells with foci (n < 5) indicates a reciprocal increase of cells with numerous punctae (5 6 n). (C) Quantiﬁcation of cells with foci/punctae in buds in (A). Cells with a
bud whose size was less than half of its mother cell were scored for whether the bud had foci/punctae or not. Note that a decrease of cells with foci/punctae in buds indicates a
reciprocal increase of cells without foci/punctae in buds. (D) Co-localization of Myo2-9myc and VCP[R155C]-EGFP expressed in wild-type. Cells grown at 25 C were stained
with anti-myc and anti-GFP antibodies and analyzed by confocal microscopy. (E) GFP ﬂuorescence and phalloidin-stained images of wild-type and myo2-66 cells expressing
VCP[R155C]-EGFP, analyzed by confocal microscopy.
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In this study, we showed that mutations observed in pathogenic
IBMPFD VCPs, which are eventually detrimental to humans, are
beneﬁcial to yeast cdc48 mutants. This suggests that these patho-
genic VCPs have some critical functions that cdc48 mutants need
for growth, which wtVCP does not provide. From this point of view,
the various amino acid substitutions observed in IBMPFD might
commonly change VCP functionally to more closely resemble
Cdc48. This idea would ﬁt well with the observations that all tested
pathogenic VCPs similarly rescued not only the ts growth of cdc48-
1 and cdc48-3 but also the lethality of the cdc48 null mutation.
However, this might not be the case, for the following reasons:
ﬁrst, all of the pathogenic mutations we tested occur on residues
conserved between yeast and human (R93, R95, R155, R159,
R191 and A232). Thus, these mutations reduced the overall amino
acid homology between the yeast and human proteins. Second,
regarding the function of substrate degradation in yeast, both
pathogenic VCPs and wtVCP behaved very similarly, but less efﬁ-
ciently than yeast Cdc48. Third, and most importantly, the patho-
genic VCPs required the Myo2-actin transport system to allow
cdc48 mutants to grow, but in wild-type yeast, the endogenous
Cdc48 protein apparently does not need the Myo2-actin transport
system for growth; i.e., myo2 mutant cells, myo2-66 and myo2-20,
are able to grow. These results imply that the pathogenic VCPs
have acquired some new functions that wtVCP and yeast Cdc48
do not possess.
The growth arrest of cdc48-1 and cdc48-3 at restrictive temper-
atures occurs in G2/M phase (Moir et al., 1982), at which the most
apparent change was the loss of progression of mitosis. Interest-
ingly, the pathogenic VCPs tended to accumulate at budding sites
and made clear foci, and this accumulation and foci formation ap-
peared to be responsible for following progression of mitosis and
eventual progression of the cell cycle in cdc48-1 and cdc48-3 mu-
tants. For these phenotypes, the pathogenic VCPs required the
Myo2-actin transport system. In this system, Myo2, a member of
the myosin V family, functions as a cage to transport cargos (mate-
rials), necessary for progression of mitosis, along actin ﬁbers to
buds, though we were unable to detect any physical interaction be-
tween the pathogenic VCPs and Myo2. We speculate that the path-
ogenic VCPs, either by chance or not, acquired a binding afﬁnity to
a yet unknown cargo(s) of the Myo2 cage, and thus were trans-
ported to buds. At restrictive temperature, the functions of
cdc48-1 and cdc48-3 proteins are weakened, to a level that is not
enough to support mitotic progression. Even in these conditions,
when high amounts of pathogenic VCPs, by themselves or as a
complex, are provided to buds via the Myo2-actin transport sys-
tem, they were able to compensate the reduced functions of
cdc48-1 and cdc48-3 proteins. We are currently investigating
whether pathogenic VCPs affect the actin-mediated transport sys-
tem in mammalian cells. Since pathogenic VCP, transfected into
mammalian cells forms foci in the presence of MG132, we tested
whether these foci would stain with a commercially-available
anti-myosin V, but this antibody was not able to detect them.
Therefore, as yet, we do not have clear evidence that similar struc-
tures exist in mammalian cells.
Interestingly, structural analysis revealed that many of the mu-
tated residues are located at the interface between the N-terminus
domain (N domain) and the ﬁrst ATPase domain (D1 domain)
(Tang et al., 2010; Fernandez-Saiz and Buchberger, 2010). Further-
more, it was proposed that altered rhythms of N domain move-
ment occur in the pathogenic VCPs, which are presumably
caused by the altered ATP hydrolysis cycle of the mutants (Tang
et al., 2010). These reports further support the idea that common
structural changes may occur in pathogenic VCPs, and thesechanges may be related to their ability to form foci in yeast as well
as the complementation of cdc48 mutants.
Since VCP is an abundant protein and interacts with many pro-
teins, a pathogenic VCP likely affects many cell functions in mam-
malian cells, whether or not they are related to IBMPFD or ALS
pathologies. Molecular promiscuity notwithstanding, IBMPFD and
ALS caused by pathogenic VCPs are autosomal dominant disorders,
and thus the pathogenic VCPs are expected to acquire common
dominant functions over the wtVCP. In this study, we showed that
all tested pathogenic VCPs could rescue the growth of cdc48-1 and
cdc48-3mutants, even in the presence of endogenous mutated pro-
teins. Although it is currently not clear that this dominant pheno-
type represents a certain disease-related disorder, further
elucidation of the mechanism underlying this phenotype may con-
tribute to the understanding of the pathology of IBMPFD and ALS.
Moreover, the yeast expressing pathogenic VCPs would provide
easy drug screening systems; e.g., screening chemical compounds
for suppression of the temperature-sensitivity, for viability, or for
foci formation would be possible, and may also contribute to the
development of new drug candidates for the treatment of IBMPFD
and ALS.
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